MariTide, a groundbreaking weight loss medication, shows 16% weight reduction in trials. Learn about this promising monthly ...

Monthly weight-loss shots on the horizon! Learn about new drugs like MariTide and why Black participation in clinical trials ...

In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic ...

Linear relationship seen for waist circumference, BP; reduction in HOMA-IR, hemoglobin A1c seen with modest weight reduction.

A post hoc analysis of the SRMOUNT-1 study finds weight loss from the use of tirzepatide was associated with strong benefits ...

A large network meta-analysis ranked eight GLP-1 receptor agonists for glycemic, weight, and safety outcomes in adults with ...

Efsitora matched or exceeded A1C reductions seen with daily basal insulin across three trials, while orforglipron demonstrated benefits for blood sugar control and weight loss at higher doses.

To put these metabolic improvements into perspective, 14-mg daily oral semaglutide (Rybelsus) yielded a 1.5% HbA1c reduction and a 4.9 kg (10.8 lbs) weight loss after 26 weeks in the PIONEER-1 trial.

Results demonstrated a weight loss of up to approximately 20% on average in participants with obesity alone and a weight loss and A1C reduction of up to approximately 17% and 2.2% on average ...

Amgen's weight-loss drug MariTide had a successful Phase 2 trial so the company is expanding development plans to study its use for heart disease and sleep apnea.

For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with ...